Stroke is one of the most devastating diseases affecting the health and life of human beings.

TBN, a novel tetramethylpyrazine derivative armed with a powerful free radical-scavenging nitrone moiety, has been reported to reduce cerebral infarction in rats through multi-functional mechanisms of action. TBN may serve as a promising new clinical candidate for the treatment of ischemic stroke.

Six Cynomolgus macaque monkeys were used for pharmacokinetic study. TBN were given intravenously at doses of 30 and 90 mg/kg, 3 monkeys for each dose.

TBN (purity 99.3%) used in this study was synthesized by Medicilon.

Reference: